Latest Ratios: P/E Ratio 106.1x · EV/EBITDA 67.8x · ROE 2.3%. (2023–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Market Cap | $4.5B | $1.7B | — | — |
| Enterprise Value | $4.1B | $1.4B | — | — |
| P/E Ratio → | 106.07 | 584.57 | — | — |
| P/S Ratio | 10.27 | 5.69 | — | — |
| P/B Ratio | 4.31 | 3.62 | — | — |
| P/FCF | 132.28 | 110.57 | — | — |
| P/OCF | 182.34 | 70.65 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| EV / Revenue | — | 4.43 | — | — |
| EV / EBITDA | 67.82 | 48.35 | — | — |
| EV / EBIT | 255.72 | 171.94 | — | — |
| EV / FCF | — | 85.94 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Gross Margin | 68.3% | 68.3% | 53.0% | 24.1% |
| Operating Margin | 5.3% | 5.3% | -30.9% | -96.9% |
| Net Profit Margin | 2.4% | 2.4% | -27.2% | -115.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ROE | 2.3% | 2.3% | -41.9% | -271.3% |
| ROA | 1.6% | 1.6% | -16.8% | -43.1% |
| ROIC | 13.5% | 13.5% | -42.8% | -65.5% |
| ROCE | 3.7% | 3.7% | -23.7% | -55.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Debt / Equity | 0.23 | 0.23 | 0.65 | 4.80 |
| Debt / EBITDA | 3.90 | 3.90 | — | — |
| Net Debt / Equity | — | -0.81 | -0.49 | 1.61 |
| Net Debt / EBITDA | -13.86 | -13.86 | — | — |
| Debt / FCF | — | -24.63 | — | — |
| Interest Coverage | 82.67 | 82.67 | -16.41 | -24.27 |
Net cash position: cash ($496M) exceeds total debt ($109M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Current Ratio | 11.69 | 11.69 | 8.03 | 1.73 |
| Quick Ratio | 11.32 | 11.32 | 7.72 | 1.62 |
| Cash Ratio | 10.34 | 10.34 | 6.75 | 1.46 |
| Asset Turnover | — | 0.48 | 0.51 | 0.37 |
| Inventory Turnover | 5.51 | 5.51 | 8.21 | 7.56 |
| Days Sales Outstanding | — | 49.79 | 59.11 | 46.26 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Earnings Yield | 0.9% | 0.2% | — | — |
| FCF Yield | 0.8% | 0.9% | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $21M | $10M | $45M |
Includes 30+ ratios · 3 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BLLN stock.
BillionToOne, Inc.'s current P/E ratio is 106.1x. This places it at the 50th percentile of its historical range.
BillionToOne, Inc.'s current EV/EBITDA is 67.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 48.4x.
BillionToOne, Inc.'s return on equity (ROE) is 2.3%. The historical average is -103.7%.
Based on historical data, BillionToOne, Inc. is trading at a P/E of 106.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
BillionToOne, Inc. has 68.3% gross margin and 5.3% operating margin.
BillionToOne, Inc.'s Debt/EBITDA ratio is 3.9x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
Thin margins versus rapid growth
Metrics are mathematically derived from official filings.
Premium Multiples Price in Sustained Growth
Based on reported figures, BLLN trades at 119.92 times trailing earnings and 77.52 times EV/EBITDA, multiples that far exceed the peer group median and imply the market is capitalizing a durable growth trajectory well beyond current profitability.
A trailing P/E near 120 and a forward P/E of 142 imply that earnings are expected to grow rather than compress, since the forward multiple is higher, which is unusual and may reflect the market discounting near-term margin conversion. Compared with ILMN at 36.6 and PGNY at 32.6, BLLN's valuation rests almost entirely on sustaining revenue growth, leaving little room for error if deceleration arrives faster than expected. Investors should monitor whether operating margin expansion can keep pace with the multiple.
Gross Margin Strength Masks Thin Conversion
As reported in the financial statements, BLLN's gross margin of 70.9% in 2026Q3 is strong, yet operating margin of 9.0% and net margin of 14.1% remain modest for a business growing above 100% year over year on a trailing basis.
The gap between gross margin near 71 percent and operating margin of 9.0% indicates that sales, R&D, and clinical adoption spending absorb most of the gross profit, which is consistent with a company still investing aggressively in growth. The net margin exceeding operating margin in the latest quarter appears to reflect non-operating or tax effects rather than core earnings power, so operating margin is the more reliable indicator of earning power here. Operating leverage has improved from negative 32.9% in 2024Q3, but has not yet reached a level that would confirm durable profitability.
Returns Recovering From Deeply Negative Base
According to recent SEC filings, BLLN's ROIC climbed from negative 2.0% in 2025Q1 to 13.0% in 2026Q1 before settling at 6.0% in 2026Q3, a trajectory that signals recovery but not yet a stable compounding profile.
The move from negative to positive ROIC over five quarters reflects improving operating results rather than a shrinking capital base, since equity has grown substantially. ROE of 3.2% and ROA of 2.3% remain low, suggesting that the large cash balance is diluting returns on equity and assets. Investors should monitor whether ROIC can hold above a double-digit level as cash is deployed, since the current figures do not yet demonstrate durable value creation.
Low Leverage Anchored by Cash Position
As reported in the financial statements, BLLN's debt-to-equity of 0.25 and debt-to-EBITDA of 8.07 in 2026Q3 reflect modest reliance on borrowing, though EBITDA-based leverage is still elevated given thin reported earnings.
A debt-to-equity ratio near 0.25 suggests the capital structure is weighted toward equity, and total debt of $140.4M is well covered by $561.5M in cash, implying a net cash position. Interest coverage of 2,899.67 times appears extraordinarily high, which may reflect minimal interest expense relative to operating income, but the figure is sensitive to small denominators and should be interpreted cautiously. Debt service appears comfortable on current figures, though the quality of EBITDA as a coverage base warrants further investigation.
Cash Accumulation May Overstate Financial Strength
Based on reported figures, the most commonly misapplied metric for BLLN is the current ratio of 11.25, which is inflated by cash reserves and obscures the company's negative retained earnings of -$231.3M and volatile quarterly cash conversion.
Diagnostic and research businesses with large cash balances often present headline liquidity ratios that look exceptional without reflecting operating efficiency, and the 11.25 current ratio is driven largely by $561.5M in cash rather than by operating assets. A more informative approach is to examine free cash flow margin trends and operating cash conversion alongside net cash, since these capture whether earnings translate into cash. The volatile series ranging from negative 23.4% to 10.1% FCF margin suggests the recent inflection may prove less durable than the latest quarter implies.